Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis

Abstract

Objective Anti–tumor necrosis factor (anti‐TNF) therapies are highly effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but a significant number of patients exhibit only a partial or no therapeutic response. Inflammation alters local and systemic metabolism, and TNF plays a role in this. We undertook this study to determine if the patient's metabolic fingerprint prior to therapy could predict responses to anti‐TNF agents. Methods Urine was collected from 16 RA patients and 20 PsA patients before and during therapy with infliximab or etanercept. Urine metabolic profiles were assessed using nuclear magnetic resonance spectroscopy. Discriminating metabolites were identified, and the relationship between metabolic profiles and clinical outcomes was assessed. Results Baseline urine metabolic profiles discriminated between RA patients who did or did not have a good response to anti‐TNF therapy according to European League Against Rheumatism criteria, with a sensitivity of 88.9% and a specificity of 85.7%, with several metabolites contributing (in particular histamine, glutamine, xanthurenic acid, and ethanolamine). There was a correlation between baseline metabolic profiles and the magnitude of change in the Disease Activity Score in 28 joints from baseline to 12 months in RA patients ( P = 0.04). In both RA and PsA, urinary metabolic profiles changed between baseline and 12 weeks of anti‐TNF therapy. Within the responders, urinary metabolite changes distinguished between etanercept and infliximab treatment. Conclusion The clear relationship between urine metabolic profiles of RA patients at baseline and their response to anti‐TNF therapy may allow development of novel approaches to the optimization of therapy. Differences in metabolic profiles during treatment with infliximab and etanercept in RA and PsA may reflect distinct mechanisms of action.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 46

1. 1.

   Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932-9.

   Not in our library10.1016/s0140-6736(99)05246-0

2. 2.

   Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis. 2000;59(Suppl 1):i46-9.

   Not in our library10.1136/ard.59.suppl_1.i46

3. 3.

   Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11.

   Not in our library10.1002/art.20217

4. 4.

   Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70(Suppl 1):i2-36.

   Not in our library10.1136/ard.2010.146852

5. 5.

   Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39:34-40.

   Not in our library10.1002/art.1780390105

6. 6.

   Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice: outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford). 2005;44:1026-31.

   Not in our library10.1093/rheumatology/keh673

7. 7.

   Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, et al. Anti-TNF α therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev. 2009;8:260-5.

   Not in our library10.1016/j.autrev.2008.11.001

8. 8.

   Rau R. Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol. 2005;24:189-202.

   Not in our library10.1007/s10067-004-0869-8

9. 9.

   Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010;6:445-51.

   Not in our library10.1038/nrrheum.2010.105

10. 10.

    Summers GD, Deighton CM, Rennie MJ, Booth AH. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford). 2008;47:1124-31.

    Not in our library10.1093/rheumatology/ken146

11. 11.

    Lin HM, Edmunds SJ, Helsby NA, Ferguson LR, Rowan DD. Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res. 2009;8:2045-57.

    Not in our library10.1021/pr800999t

12. 12.

    Bezabeh T, Somorjai RL, Smith IC. MR metabolomics of fecal extracts: applications in the study of bowel diseases. Magn Reson Chem. 2009;47:S54-61.

    Not in our library10.1002/mrc.2530

13. 13.

    Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-51.

    Not in our library10.1021/pr060470d

14. 14.

    Young SP, Nessim M, Falciani F, Trevino V, Banerjee SP, Scott RA, et al. Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease. Mol Vis. 2009;15:1210-7.

    Not in our library

15. 15.

    Sinclair AJ, Viant MR, Ball AK, Burdon MA, Walker EA, Stewart PM, et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases—a diagnostic tool? NMR Biomed. 2010;23:123-32.

    Not in our library10.1002/nbm.1428

16. 16.

    Pan XY, Wilson M, Mirbahai L, McConville C, Arvanitis TN, Griffin JL, et al. In vitro metabonomic study detects increases in UDP-GlcNAc and UDP-GalNAc, as early phase markers of cisplatin treatment response in brain tumor cells. J Proteome Res. 2011;10:3493-500.

    Not in our library10.1021/pr200114v

17. 17.

    Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu JD, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.

    Not in our library10.1038/nature07762

18. 18.

    Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002;8:1439-44.

    Not in our library10.1038/nm1202-802

19. 19.

    Schicho R, Nazyrova A, Shaykhutdinov R, Duggan G, Vogel HJ, Storr M. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by 1H NMR spectroscopy. J Proteome Res. 2010;9:6265-73.

    Not in our library10.1021/pr100547y

20. 20.

    Murdoch TB, Fu H, MacFarlane S, Sydora BC, Fedorak RN, Slupsky CM. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem. 2008;80:5524-31.

    Not in our library10.1021/ac8005236

21. 21.

    Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435-44.

    Not in our library10.1038/ajg.2009.175

22. 22.

    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

    Not in our library10.1002/art.1780310302

23. 23.

    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.

    Not in our library10.1002/art.1780380107

24. 24.

    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.

    Not in our library10.1002/art.1780230202

25. 25.

    Van Gestel AM, Haagsma CJ, Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-50.

    Not in our library10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k

26. 26.

    Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1996;39:2013-20.

    Not in our library10.1002/art.1780391210

27. 27.

    Viant MR, Ludwig C, Rhodes S, Guenther UL, Allaway D. Validation of a urine metabolome fingerprint in dog for phenotypic classification. Metabolomics. 2007;3:453-63.

    Not in our library

28. 28.

    Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun. 2003;310:943-8.

    Not in our library10.1016/j.bbrc.2003.09.092

29. 29.

    Liu M, Wang GR, Liu TZ, Tsai KJ. Improved fluorometric quantification of urinary xanthurenic acid. Clin Chem. 1996;42:397-401.

    Not in our library

30. 30.

    Chauchard F, Cogdill R, Roussel S, Roger JM, Bellon-Maurel V. Application of LS-SVM to non-linear phenomena in NIR spectroscopy: development of a robust and portable sensor for acidity prediction in grapes. Chemometr Intell Lab Syst. 2004;71:141-50.

    Not in our library

31. 31.

    Trevino V, Falciani F. GALGO: an R package for multivariate variable selection using genetic algorithms. Bioinformatics. 2006;22:1154-6.

    Not in our library10.1093/bioinformatics/btl074

32. 32.

    Pedersen LM, Nordin H, Svensson B, Bliddal H. Microalbuminuria in patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:189-92.

    Not in our library10.1136/ard.54.3.189

33. 33.

    Niederstadt C, Happ T, Tatsis E, Schnabel A, Steinhoff J. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:28-33.

    Not in our library10.1093/rheumatology/38.1.28

34. 34.

    Ramadan Z, Jacobs D, Grigorov M, Kochhar S. Metabolic profiling using principal component analysis, discriminant partial least squares, and genetic algorithms. Talanta. 2006;68:1683-91.

    Not in our library10.1016/j.talanta.2005.08.042

35. 35.

    Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol. 2002;97:3071-7.

    Not in our library10.1111/j.1572-0241.2002.07028.x

36. 36.

    Buckley MG, Walters C, Wong WM, Cawley MI, Ren S, Schwartz LB, et al. Mast cell activation in arthritis: detection of α- and β-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci (Lond). 1997;93:363-70.

    Not in our library10.1042/cs0930363

37. 37.

    Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997;40:217-25.

    Not in our library10.1002/art.1780400206

38. 38.

    Stifel FB, Herman RH. Histidine metabolism. Am J Clin Nutr. 1971;24:207-17.

    Not in our library10.1093/ajcn/24.2.207

39. 39.

    Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol. 1991;260:E727-30.

    Not in our library10.1152/ajpendo.1991.260.5.e727

40. 40.

    Sitton NG, Dixon JS, Bird HA, Wright V. Serum biochemistry in rheumatoid arthritis, seronegative arthropathies, osteoarthritis, SLE and normal subjects. Br J Rheumatol. 1987;26:131-5.

    Not in our library10.1093/rheumatology/26.2.131

Cited by papers we hold 5

• Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity · 2021
  Not checked
• Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses · 2019
  Not checked
• ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis. · 2015
  Not checked
• The interplay between inflammation and metabolism in rheumatoid arthritis · 2015
  No notice
• The Impact of Inflammation on Metabolomic Profiles in Patients With Arthritis · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.